Nelfinavir mesylate: A protease inhibitor

Annals of Pharmacotherapy

Volumn 33, Issue 3, 1999, Pages 325-339

  Pai, Vinita B ^a,b   Nahata, Milap C ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Human immunodeficiency virus; Nelfinavir mesylate

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; BENZODIAZEPINE DERIVATIVE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; BLEEDING; COST BENEFIT ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; HEMATOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUTROPENIA; PRIORITY JOURNAL; RASH; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VIRUS LOAD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DRUG INTERACTIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR;

EID: 0032895879     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18089     Document Type: Review

References (64)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 1998;10(1).
2. Centers for Disease Control and Prevention. Report of the NIH Panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998;47(no. RR-5).
3. Longer M, Shetty B, Zamansky I, Tyle P. Preformulation studies of a novel HIV protease inhibitor, AG1343. J Pharm Sci 1995;84:1090-3.
4. Debouck C, Metcalf BW. Human immunodeficiency virus protease: target for AIDS therapy. Drug Dev Res 1990;21:1-17.
5. Mitsuya H, Yarchoan R, Kageyama S, Broder S. Target therapy of human immunodeficiency virus related disease. FASEB J 1990;5:2369-81.
6. Robins T, Plattner J. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr 1993;6:162-70.
7. Navia MA, Fitzgerald P, McKeever BM, Leu CT, Heimbach JC, Herber WK, et al. Three-dimensional structure of aspartyl protease from HIV-1. Nature 1989;337:615-20.
8. Wlodawer A, Miller M, Jaskolski M, Sathnarayana BK, Baldwin E, Weber IT, et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989;245:616-21.
9. Patick AK, Mo H, Markowitz M, Appell K, Wu B, Musick L, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996;40:292-7.
10. Nunberg JH, Sheif WA, Boots EJ, O'Brien JM, Quintero JC, Hoffmann JM, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991;65:4887-92.
11. El-Farrash MA, Kuroda MJ, Kitazaki T, Masuda K, Kato K, Hatanaka M, et al. Generation and characterization of human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol 1994;68:233-9.
12. 2-symmetric protease inhibitor. J Virol 1994; 68:2016-20.
13. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB, et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor R031-8959. Virology 1995;206:527-34.
14. Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, Everitt L, et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA 1994;91:5597-601.
15. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995;69:701-6.
16. Otto MJ, Garber S, Winslow DL, Reid CD, Aldrich P, Jadhav PK, et al. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitor of HIV type 1 protease. Proc Natl Acad Sci U S A 1993;90:7543-7.
17. Otto MJ, Reid CD, Garber S, Lam PY-S, Scarnati H, Bacheler LT, et al. In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob Agents Chemother 1993;37: 2606-11.
18. Patick AK, Rose R, Greytok J, Bechtold CM, Hermsmeier MA, Chen PT, et al. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol 1995;69:2148-52.
19. Potts KE, Smidt ML, Stallings WC Jr, Clare M, Pillay D, Richman DD, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) variants with decreased sensitivity to hydroxyethylurea isostere containing protease inhibitors. 3rd International Workshop on HIV Drug Resistance, London, 1994.
20. Tisdale M, Myers R, Parry NR, Oliver N, Maschera B, Blair E. Comprehensive analysis of HIV-1 variants individually selected for resistance to six HIV protease inhibitors. 3rd International Workshop on HIV Drug Resistance, London, 1994.
21. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994;91:4096-100.
22. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996;51(5):701-12.
23. Tamlet C, Poizot Martin IP, Lafeuillade A, Yahi N, Vigne R, Eissot Dupont H, et al. Viral load and genotypic resistance pattern in HIV-1 infected patients treated by a triple combination therapy including nucleoside and protease inhibitors initiated at primary infection. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
24. FDA Public Health Advisory. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). Rockville, MD: Food and Drug Administration Center for Drug Evaluation and Research, June 11, 1997.
25. Conant M, Markowitz M, Hurley A, Ho D, Peterkin J, Chapman S. A randomized Phase II dose range-finding study of the HIV protease inhibitor Viracept as monotherapy in HIV positive patients. XI International Conference on AIDS, Vancouver, BC, Canada, July 7-12, 1996.
26. Patick AK, Duran M, Cao Y, Ho T, Zhou P, Keller MR, et al. Genotypic analysis of HIV-1 variants isolated from patients with the protease inhibitor nelfinavir, alone or in combination with stavudine or zidovudine and lamivudine. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
27. Hertogs K, Mellors JW, Schel P, Van Cauwenberghe A, Pauwels R. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
28. Quart BD, Chapman SK, Peterkin J, Webber S, Oliver S. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343 - a novel HIV protease inhibitor. 2nd National Conference on Human Retrovirus, Washington, DC, January 29-February 2, 1995.
29. Shetty BV, Kosa MB, Khalil DA, Webber S. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996; 40:110-4.
30. Product information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., 1998.
31. Krogstad P, Kerr B, Anderson R, Hendricks A, Luzuriaga K, Wiznia A, et al. Phase I study of the HIV-protease inhibitor nelfinavir mesylate (NFV) in HIV positive children. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
32. Data submitted to Department of Health and Human Services for NDA approval. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., 1997.
33. Kerr B, Lee C, Yuen G, Anderson R, Daniels R, Grettenberger H, et al. Overview of in vitro and in vivo drug interaction studies of nelfinavir mesylate (NFV) a new HIV-1 protease inhibitor. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
34. Powderly W, Sension M, Conant M, Stein A, Clendeninn N. The efficacy of Viracept (nelfinavir mesylate, NFV) in pivotal Phase II/III double blind randomized controlled trials as monotherapy and in combination with stavudine or zidovudine/lamivudine. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
35. Henry K, Lamarca A, Myers R, Chapman S. The safety of Viracept (nelfinavir mesylate, NFV) in pivotal Phase II/III double-blind randomized controlled trials as monotherapy and in combination with either stavudine or zidovudine/lamivudine. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
36. Clendeninn N, Quart BD, Anderson R, Knowles M, Chang Y. Analysis of long-term virologic data from the Viracept (nelfinavir, NFV) 511 protocol using 3 HIV-RNA assay. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
37. Markowitz M, Cao Y, Hurley A, O'Donovan R, Peterkin J, Anderson B, et al. Triple therapy with zidovudine and lamivudine in combination with nelfinavir mesylate in 12 antiretroviral-naïve subjects chronically infected with HIV-1. XI International Conference on AIDS, Vancouver, BC, Canada, July 7-12, 1996.
38. Pedneault L, Elion R, Adler M, Anderson R, Mohanty S, Knupp C, et al. A pilot study of safety and antiviral activity of the combination of stavudine, didanosine and nelfinavir in HIV-infected subjects (abstract). AIDS 1996;10(suppl 2):S17.
39. Pedneault L, Elion R, Adler M, Anderson R, Kelleher T, Knupp C, et al. Stavudine (d4T), didanosine (ddI), and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
40. Skowron G, Leoung G, Dusek A, Anderson R, Grosso R, Lamson M, et al. Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP) preliminary safety, activity and pharmacokinetic interactions. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
41. Kravcik S, Farnsworth A, Patick A, Duncan I, Hawley-Foss, Anderson R, et al. Long term follow-up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
42. Opravil M on behalf of the SPICE study team. Study of Protease Inhibitor Combination in Europe (SPICE): saquinavir soft gelatin capsule (SQV-SGC) and nelfinavir in HIV infected individuals. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
43. Gallant J, Heath-Chiozzi M, Raines C, Anderson R, Katz T, Fields C, et al. Safety and efficacy of nelfinavir-ritonavir combination therapy. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
44. Johnson M, Petersen A, Winslade J, Clendeninn N. Comparison of bid and tid dosing of Viracept (nelfinavir, NFV) in combination with stavudine (d4T) and lamivudine (3TC). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
45. Sension M, Elion R, Farthing C, Currier J, Lindquist B, Richardson B, et al. Open label pilot study to assess the safety and efficacy of bid dosing regimens of Viracept (nelfnavir mesylate) combined with NRTI's in HIV-infected treatment-naïve patients. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
46. Data on file. La Jolla, CA: Agouron Pharmaceuticals, Inc., 1997.
47. Workman C, Mussen R, Sullivan J. Salvage therapy using six drugs in heavily pretreated patients. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
48. Gerard M, De Wit S, Sprecher S, De Cock F, Van Laethem Y, Hermans P, et al. Salvage anti-HIV triple therapy with Foscarnet (F) in combination with nelfinavir in heavily pretreated patients (P). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
49. Ballard C, Toerner JG, Colwell B, Mathews WC. Early CD4, viral load and quality of life response to salvage treatment with nelfinavir: the USCD Owen Clinic Nelfinavir Expanded Access Experience. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
50. Tsoukas C, Belanger G, Bond M. Increased incidence of bleeding episodes in persons with hemophilia in association with protease inhibitor antiretroviral therapy. Canadian Conference of HIV/AIDS Research, Ottawa, ON, Canada, May 22-25, 1997.
51. Hengel RL, Geary JAM, Vuchetich MA, Swartz AS, Brachman PS, Watts NB, et al. Multiple symmetrical lipomatosis associated with protease inhibitor therapy. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
52. Rosenberg HE, Mulder J, Sepkowitz KA, Giordano MF. "Protease paunch" in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
53. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Buffalo hump in HIV infected patients on antiretroviral therapy. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
54. Carr A, Samaras K, Burton S, Freund J, Chishsolm DJ, Cooper DA. A syndrome of peripheral lipodystrophy [LD] hyperlipidemia and insulin resistance due to HIV protease inhibitors [PI's]. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
55. Roth VR, Angel JB, Kravcik S. Development of cervical fat pad following treatment with HIV-1 protease inhibitors. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
56. Miller K, Jones E, Yanovski J, Shankar R, Feuerstein I, Falloon J. Increased intra-abdominal fat deposits in patients on indinavir. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
57. Carr A, Samaras K, Burton S, Chishsolm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351:1881-3.
58. Havlir D, Riddler S, Squires K, Winslow D, Kerr B, Nguyen B, et al. Co-administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity results. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
59. Merry C, Barry M, Mulcahy F, Back D. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV infected patients. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
60. Merry C. Barry MG, Mulcahy FM, Ryan M, Tija JF, Halifax KL, et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 1998;12:1163-7.
61. Skowron G, Leoung G, Kerr B, Dusek A, Anderson R, Beebe S, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 1998;12:1243-4.
62. Fiske WD, Beneder IH, White SJ, Pepperess KA, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
63. Cox SR, Schneck DW, Herman BD, Carel BJ, Gullotti BR, Kerr BM, et al. Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
64. 1998 Drug topics red book. Montvale, NJ: Medical Economics Co., Inc., 1998:590.